Loading clinical trials...

The Effects of a Nutritional Supplement on Sleep Quality | Clinical Trials | Clareo Health

RECRUITINGNA

The Effects of a Nutritional Supplement on Sleep Quality

NCT07345260•Athletic Greens International

Summary

This study is a randomized, double-blind, placebo-controlled study of N=140 adult men and women with sub-clinical sleep issues. This study to assess the effect of a novel dietary supplement on sleep related outcomes.

Eligibility

Age

35 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Be male or female
•2. Be aged 35-65.
•3. Body Mass Index: ≥18.5 and ≤29.9 kg/m2
•4. Anyone currently experiencing issues with falling asleep, staying asleep, or waking up during the night
•5. Score of 7 or less on the RU-SATED validated sleep questionnaire.
•6. Anyone willing to follow the study protocol.
•7. Anyone willing to discontinue any other supplements (nootroptics, adaptogens, calming herbs), medications, herbal remedies, over the counter sleep medications \[e.g., zolipidem, diphenhydramine (Benadryl or unisom), magnesium or melatonin products\] used to assist with sleep for the duration of the study.
•8. Agree to limit alcohol intake within \~4 hours of bedtime
•9. Agree to limit caffeine intake to ≤ 400 mg/day (\~3-4 cups of coffee) or ingestion of caffeine-containing products after 2:00 PM during the study period.
•10. Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
+1 more criteria

Exclusion Criteria

•1. Anyone with a diagnosed chronic sleep condition, including but not limited to insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome (RLS), or sleep apnea.
•2. Women currently undergoing perimenopause or experiencing vasomotor symptoms such as night sweats.
•3. Use of hormone therapy (including estrogen, progesterone, or phytoestrogens) within the last 3 months.
•4. Anyone with diagnosed psychiatric disorders including major depressive disorder with acute symptoms, Bipolar disorder, Generalized anxiety disorder with active symptoms, PTSD with frequent nightmares
•5. Anyone with diagnosed neurogenitive diseases or chronic pain disorders including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia
•6. Anyone who regularly consumes prescribed stimulant medications including Amphetamines (e.g., Adderall, Vyvanse), Methylphenidate (e.g., Ritalin, Concerta), and Modafinil / Armodafinil
•7. Anyone currently on CNS activating anti-depressants including Bupropion (Wellbutrin), Fluoxetine, Venlafaxine (Effexor), Sertraline (Zoloft).
•8. Current or recent use of cannabis or THC-containing products, including recreational or medicinal marijuana, CBD products with measurable THC content, or synthetic cannabinoids, within the past 30 days.
•9. Anyone with a job that disrupts their nighttime sleep (e.g., excessive travel, night/3rd shift workers).
•10. Anyone unwilling to wear the Oura ring device for the duration of the trial or unwilling to open the Oura application at least three times each week during the trial for data to sync to the cloud
+7 more criteria

Locations (1)

Citruslabs

Santa Monica, California, United States

Key Dates

Start Date

January 2, 2026

Primary Completion Date

April 30, 2026

Completion Date

May 30, 2026

Last Updated

February 10, 2026

Enrollment

140

ESTIMATED participants

Conditions

SleepSleep Quality

Interventions

Novel powdered sleep supplement

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Contacts

Principal Investigator

CONTACT

(805) 292-0714 ellen@citruslabs.com

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

NCT01778504

Neuropsychiatric DisorderNeurological Disorder+2 more

View study

RECRUITING

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

NCT06430957

Obstructive Sleep Apnea Risk ManagementPostoperative Complications+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effects of a Nutritional Supplement on Sleep Quality

Inclusion Criteria

Exclusion Criteria

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

Light Exposure, Migraine Outcomes, and Sleep Quality

MyVitalC: Sleep and Everyday Headache Management

Digital-supported Orofacial Myofunctional Therapy in OSA

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder